Skip to main content
CDC Website

MMWR: Updated Guidelines for the Use of Rifabutin or Rifampin for the Treatment and Prevention of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors

This guideline presents updated data about drug interactions between protease inhibitors and non-nucleoside reverse transcriptase inhibitors for treatment of HIV infection together with rifamycins for treatment of TB.

Author:
Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Office of the Morbidity and Mortality Weekly Report Series, CDC MMWR
Focus Area:
TB
Subjects:
Case Management
Treatment Guidelines Materials
HIV Co-infection
Treatment- TB Disease
TB Treatment
Treatment- Medication Information
Publication Date:
2000
Format:
Guideline
6 p.: b&w; refs., tables.
Links:
http://www.cdc.gov/mmwr/PDF/wk/mm4909.pdf
Links:
Last Updated Date:
Publication ID:
31318